APON(300753)2024-04-25 13:12Financial Performance - The company's operating revenue for Q1 2024 was ¥87,752,962, a decrease of 6.71% compared to ¥94,068,177 in the same period last year[5] - Net profit attributable to shareholders increased by 11.63% to ¥1,356,953.49 from ¥1,215,574.66 year-on-year[5] - The net profit after deducting non-recurring gains and losses surged by 76.41% to ¥1,720,177.95 compared to ¥975,082.81 in the previous year[5] - Net profit for Q1 2024 was CNY 1,127,308.15, a decrease of 9.8% from CNY 1,250,235.16 in Q1 2023[24] - Total operating revenue for Q1 2024 was CNY 87,752,962, a decrease of 6.0% compared to CNY 94,068,177.53 in Q1 2023[23] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥64,053,023.05, slightly worse than -¥60,865,461.63 in the same period last year, reflecting a decline of 5.24%[5] - The company's cash and cash equivalents decreased significantly by 76.13% to ¥47,944,359.60 due to investments in financial products[10] - The cash flow from financing activities showed a net inflow of ¥8,339,252.52, compared to a net outflow of ¥1,463,619.19 in the previous year[27] - The total cash and cash equivalents at the end of the period were ¥47,944,359.60, a decrease from ¥200,896,344.58 at the beginning of the period[27] - The cash and cash equivalents net increase was -¥152,951,984.98, compared to -¥205,250,243.54 in the same period last year[27] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥843,679,848.99, down 1.85% from ¥859,572,978.63 at the end of the previous year[5] - The total liabilities decreased to CNY 145,266,713.67 from CNY 162,377,151.47, reflecting a reduction of 10.5%[24] - The total current liabilities decreased to CNY 112,087,318.16 from CNY 129,873,385.02, a reduction of about 13.7%[20] - The total non-current assets amounted to CNY 413,540,432.67, slightly down from CNY 417,269,663.85[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,868[12] - The company reported a total of 45,053,063 shares under lock-up agreements, with a planned release date of August 6, 2025[16] - The company plans to increase its shareholding by at least CNY 5.4 million within six months from February 6, 2024, using self-raised funds[17] Operational Metrics - The company's cash received from sales of goods and services was CNY 69,016,477.25, down 13.8% from CNY 80,064,517.56 in Q1 2023[25] - Research and development expenses were CNY 7,677,023.64, down 20.7% from CNY 9,687,121.04 in Q1 2023[24] - Sales expenses decreased to CNY 24,765,360.77, a reduction of 21.0% from CNY 31,384,618.87 in the previous year[24] - Accounts receivable increased to CNY 162,468,844.13 from CNY 148,402,423.90, reflecting a growth of approximately 9.5%[19] - The company's inventory rose to CNY 59,059,390.73 from CNY 55,688,087.49, representing an increase of about 4.9%[19] - Short-term borrowings increased to CNY 49,237,875.14 from CNY 39,237,875.14, showing a rise of approximately 25.5%[20] Other Income and Expenses - Other income dropped by 82.84% to ¥1,263,464.93, primarily due to the absence of tax refunds[10] - Total operating costs decreased to CNY 86,636,436.82, down 12.5% from CNY 99,122,242.30 in the previous year[23] - The company distributed dividends and profits amounting to ¥332,166.81, slightly up from ¥322,328.19 year-over-year[27] - The cash outflow from financing activities totaled ¥1,750,747.48, a significant decrease from ¥11,363,619.19 in the previous year[27] Regulatory and Compliance - The company has not undergone an audit for the first quarter report[28] - Jiangsu Aipeng's subsidiary, Sichuan Jinjiazheng Medical Equipment Co., Ltd., received a medical device registration certificate for a third-class anesthesia depth monitor on February 5, 2024[17]